AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03189992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bushen-Jianpi Dedoction
Description: A traditional chinese medicine prescription
Study NCT03189992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinobufotalin injection
Description: an effective Chinese preparation to treat malignant tumor.
Study NCT03189992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cinobufotalin injection
Description: an effective Chinese preparation to treat malignant tumor.
Study NCT03381170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E
Study NCT00978614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane
Description: Dosage form:~25 mg immediate release \[IR\] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)
Study NCT03905694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered by subcutaneous (SC) injection.
Study NCT01749423 — intervention group
Intervention type: BIOLOGICAL
Intervention: OnabotulinumtoxinA
Description: Previous treatment with onabotulinumtoxinA for Chronic Migraine.
Study NCT00704132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin phosphate
Description: Sitagliptin tablet 100 mg, administered once daily before the morning meal.
Study NCT02253485 — intervention group
Intervention type: DRUG
Intervention: telbivudine
Description: in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.~in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV.
Study NCT00704132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Matching placebo tablet, administered once daily before the morning meal.
Study NCT00504751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, dexamethasone, ifosfamide
Description: VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5
Study NCT01969435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Study NCT01969435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Study NCT01969435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT01969435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan HCl (propylene glycol-free)
Study NCT03207594 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.
Study NCT03207594 — intervention group
Intervention type: OTHER
Intervention: Saliva sample
Description: Subjects will have saliva collected by a member of the study team using a cotton swab.
Study NCT03207594 — intervention group
Intervention type: OTHER
Intervention: Smoking Status questions
Description: Subjects will be asked to complete an assessment asking questions about his/her current smoking status
Study NCT06173908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cell treatment
Description: Autologous epidermal basal cells were used to repair nonhealing postoperative wound
Study NCT06173908 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control treatment
Description: anyother treatments except autologous epidermal basal cells were used to repair nonhealing postoperative wound
Study NCT01297725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blunt right, sharp left
Description: Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
Study NCT01297725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blunt left, sharp right
Description: Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
Study NCT01161537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: Tablet.
Study NCT01161537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet.
Study NCT03764306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Artery Stenting
Description: Carotid artery stenting was considered successful if there was no residual stenosis greater than 20%, and there was no dissection of target artery following the procedure.
Study NCT03764306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endarterectomy carotid artery
Description: Surgical endarterectomy was considered successful if there was no residual stenosis after procedure, without symptoms.
Study NCT03853525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Description: Product is applied to one side of the inguinal region.
Study NCT02215135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
Study NCT01673620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/loratadine 10 mg
Description: Montelukast 10 mg/loratadine 10 mg tablet administered once daily
Study NCT01673620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet administered once daily
Study NCT02843828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait rehabilitation with Samsung Hip Assist v1
Description: Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
Study NCT02843828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait rehabilitation without Samsung Hip Assist v1
Description: Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
Study NCT01916343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Laparoscopic Curriculum
Study NCT04397562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levilimab
Description: Levilimab 324 mg
Study NCT04397562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02100969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIZENTRA ®
Description: Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
Study NCT01629953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group vocational intervention
Description: Group based manualized vocational rehabilitation
Study NCT01629953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supported Employment Condition
Description: Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
Study NCT01510743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization of subclavian vein
Description: Catheterization of subclavian vein
Study NCT01510743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization of internal jugular vein
Description: Catheterization of internal jugular vein
Study NCT01504841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.
Study NCT01335269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 853520
Description: BI 853520 once daily in a dose escalation schedule
Study NCT04483336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Virtual reality goggles are commercially available wearable devices that are used to view view videos and play video games three dimensionally.
Study NCT04483336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TV Screen Distraction
Description: A cartoon video was played on a regular TV screen.
Study NCT00005085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Study NCT03305978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra low dose chest CT
Description: An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.
Study NCT03305978 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low dose chest CT
Description: standard diagnostic low dose chest CT
Study NCT03295773 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3DRA
Study NCT02166268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVANZ Phleum pratense 15,000 SQ+
Study NCT02166268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02146638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02146638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT02146001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reducing sedentary behavior group
Description: This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
Study NCT02146001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-to-vigorous activity group
Description: This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
Study NCT04090463 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy
Description: IORT will be delivered as follows:~1. Radical resection --> delivery of 10-15 Gy to the tumor bed~2. Non radical resection --> delivery of 15-20 Gy to the tumor in situ
Study NCT01834079 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STEM CELL THERAPY
Description: Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
Study NCT04776863 — intervention group
Intervention type: DEVICE
Intervention: optical biometry measurement
Description: The measurements of the individuals using smokeless tobacco and those who do not were taken by optical biometry.
Study NCT01484574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stem Cells
Description: Single intramuscular administration of low dose of stem cells
Study NCT01484574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stem Cells
Description: Single intramuscular administration of intermediate dose of stem cells
Study NCT04366167 — intervention group
Intervention type: OTHER
Intervention: Cardiac surgery
Description: Cardiac surgery during the COVID-19 pandemic
Study NCT01069133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550mg BID open-label
Study NCT01069133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximin
Description: 550mg PO BID
Study NCT02853240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
Study NCT04179253 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: office micro hysteroscopy
Description: One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
Study NCT03846609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double balloon interventional platform (DiLumen)
Description: double balloon interventional platform (DiLumen) is used for removal of colonic polyp
Study NCT03846609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: no double balloon interventional platform (DiLumen)
Description: double balloon interventional platform (DiLumen) is not used for removal of colonic polyp
Study NCT03853525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Description: Product is applied to one side of the inguinal region.
Study NCT01616485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-1790
Description: 2 TA-1790 100 mg capsules
Study NCT01616485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Description: 2 sildenafil citrate 50 mg capsules
Study NCT02783599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV
Study NCT02783599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered IV
Study NCT02783599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Study NCT01616485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules for TA-1790 100 mg capsules
Study NCT01616485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrostat
Description: glyceryl trinitrate tablet, USP 0.4 mg
Study NCT01616485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrostat
Description: glyceryl trinitrate tablet, USP 0.4 mg
Study NCT01616485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrostat
Description: glyceryl trinitrate tablet, USP 0.4 mg
Study NCT00772356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Spirit Insulin Pump
Study NCT00772356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator insulin pump
Study NCT01810029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation plus Transcendental Meditation
Description: The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
Study NCT01810029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation plus Transcendental Meditation
Description: The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
Study NCT01280552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICT-107
Description: Autologous dendritic cells pulsed with immunogenic antigens
Study NCT03853525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semisolid vaseline
Description: Product is applied to one side of the inguinal region.
Study NCT01280552 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DC
Description: Autologous dendritic cells (DC) that have not been pulsed with antigens
Study NCT03774589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Compressive Anastomosis
Description: The magnetic compressive anastomosis will be used to complete the anastomosis during bilioenteric anastomosis.
Study NCT03774589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Anastomosis
Description: A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
Study NCT02522390 — intervention group
Intervention type: OTHER
Intervention: Research activities
Description: Measurements are primarily based on do-it-yourself non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.~The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts.
Study NCT04151290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognoa ASD diagnostic device
Description: Cognoa device is intended to aid healthcare providers in diagnosing Autism Spectrum Disorder (ASD)
Study NCT01411163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Up to 30 grams daily creatine monohydrate
Study NCT00511693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: centralized osteoporosis coordinator
Description: The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
Study NCT00511693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: fall prevention
Description: Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
Study NCT04636333 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#
Description: Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
Study NCT03496142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal prostate biopsy
Description: Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
Study NCT03496142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal prostate biopsy
Description: Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
Study NCT01936116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sonohysterography with inflated catheter in uterine cavity
Description: during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
Study NCT01936116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sonohysterography with inflated catheter in cervical cavity
Description: During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
Study NCT00754754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Retraction Monitoring Sensor
Description: This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
Study NCT00718328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Description: Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.